Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the updraftplus domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /home/vestivxx/public_html/wp-includes/functions.php on line 6114

Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wprss domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /home/vestivxx/public_html/wp-includes/functions.php on line 6114

Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wprss domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /home/vestivxx/public_html/wp-includes/functions.php on line 6114
Shares in this FTSE 100 Dividend Aristocrat are trading at a record low multiple – Vested Daily

Shares in this FTSE 100 Dividend Aristocrat are trading at a record low multiple

Shares in businesses that have increased their dividend per share for 25 consecutive years can be great sources of passive income. Especially when they’re cheap. 

Croda International‘s (LSE:CRDA) a FTSE 100 company that makes speciality chemicals. It has a strong dividend record and from a valuation perspective, it just became historically cheap.

Dividends

Stocks don’t get to be Dividend Aristocrats by accident. It doesn’t guarantee anything going forward, but it’s a sign of a strong business.

With Croda, there are two key advantages. The first is the number of patents that protect its products – over 1,600 across more than 275 families. The second is that its drug delivery systems are often specified as part of regulatory approval. That makes it impossible for pharmaceutical firms to switch to a different product.

That’s why Croda’s been able to increase its dividend each year since 1991. Despite ups and downs in the company’s earnings, the firm has distributed more and more to investors. 

The P/E ratio

At first sight, it doesn’t look like much of a bargain at the moment. A price-to-earnings (P/E) multiple of 30 is high relative to both the company’s history and the FTSE 100 average.

Croda International P/E ratio 2005-24

Created at TradingView

The trouble is, the P/E ratio can be highly misleading with this type of business. That’s because earnings can be quite volatile, causing the multiple to shift dramatically.

In 2022, for example, the stock traded at a P/E multiple of around 13. But that’s because profits were being boosted by unusually high demand for vaccines during the Covid-19 pandemic.

Croda International earnings per share 2019-24


Created at TradingView

As that’s subsided, earnings have fallen away sharply. As a result, the P/E multiple has more than doubled even though the share price is down around 50%.

Valuation

With Croda, I think the price-to-book (P/B) ratio‘s a much more useful valuation metric. The value of the company’s assets minus its liabilities is much less volatile than its net income.

Croda International P/B ratio 2005-24


Created at TradingView

From this perspective, the stock’s historically cheap. At a P/B multiple of close to 2, Croda shares are better value – from this perspective – than they have been at any point since 2005.

I think this is a good indication of how cheap the stock is, but there’s a catch. Outside the pandemic, the return the company earns on its equity has been falling consistently since 2010.

Croda International return on equity 2005-24


Created at TradingView

Part of this is due to earnings volatility, but a 15-year trend can’t just be put down to cyclical fluctuations. The possibility of this continuing is the biggest risk investors currently face.

A buying opportunity?

The falling return on equity goes some way towards explaining why the stock’s been trading at an increasingly low P/B multiple. Croda doesn’t earn the return on its assets it once did.

Equally though, this hasn’t stopped the company increasing its dividend with spectacular consistency. And for that reason alone I think passive income investors should pay attention. 

All of this leaves me undecided on what to do. But I’m clear that the current valuation’s the best opportunity I’ve seen when it comes to buying Croda shares.

This post was originally published on Motley Fool

Financial News

Daily News on Investing, Personal Finance, Markets, and more!